Wei-Ying Jen
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Acquired aplastic anemia (AA) can present similarly to inherited bone marrow failure syndromes (IBMFS) but treatment differs. AA diagnosis relies on excluding IBMFS; however, genetic testing is not always available, may delay care or be inconclusive. We developed the Predictive Aplastic Score System (PASS), a clinical tool using readily available data to distinguish AA from IBMFS in adults. The training cohort included 212 adults (162 AA, 50 IBMFS). Compared to IBMFS, AA patients were older and more likely to have acute-onset, severe cytopenias. Using logistic regression with LASSO, we selected seven clinical variables for model inclusion: severity, acuity, age, IBMFS red flags, AA-associated conditions, AA-associated somatic changes, and telomere lengths. The model achieved AUC of 0.990 (95% CI: 0.982–0.999), with 100% positive predictive value (PPV) for AA for scores ≥ 30. 86.8% of patients with scores < 0 had IBMFS. We validated PASS in 716 patients from four external cohorts with AUC of 0.977 (95% CI: 0.968–0.987). Threshold analysis confirmed 100% PPV for scores ≥ 30, rapidly diagnosing 80% of AA cases. PASS is a practical and accurate clinical tool that can rapidly distinguish AA from IBMFS for most adult patients. To promote clinical adoption, we developed open-access web calculator (https://pennmedicine.shinyapps.io/passcalc/).
Year:
2026
Background The prognostic impact of Fms‐like tyrosine kinase 3 ( FLT3 )‐tyrosine kinase domain (TKD) mutation in patients with acute myeloid leukemia (AML) is not well defined. The authors described outcomes of one of the largest cohorts of patients with FLT3 ‐TKD mutated ( FLT3 ‐TKD mut ) AML to date. Methods This retrospective study included patients with newly diagnosed AML who received frontline treatment at The University of Texas MD Anderson Cancer Center from January 2012 to March 2024 divided into two cohorts: FLT3 ‐TKD mut AML and nucleophosmin‐mutated ( NPM1 mut )/ FLT3 ‐TKD wild‐type ( FLT3 ‐TKD wt ) AML. Patients with FLT3 internal tandem duplication mutations were excluded. Results In total, 2922 patients were screened, and 250 met inclusion criteria, including 124 patients with FLT3 ‐TKD mut AML and 126 patients with NPM1 mut / FLT3 ‐TKD wt AML. In the FLT3 ‐TKD mut cohort ( n = 124), intensive chemotherapy was received by 54 patients (44%), with a composite complete remission in 81% and a 3‐year overall survival (OS) rate of 56%. An NPM1 mutation was noted in 24 patients (44%) who had improved OS (3‐year OS, 74% vs. 40%; p = .03). Allogeneic stem cell transplantation improved OS in patients who had NPM1 wt AML (3‐year OS, 89% vs. 30%; p = .02) but not in those who had an NPM1 mutation. Lower intensity therapy was received by 70 patients (56%), with a composite complete remission in 63% and a 3‐year OS rate of 23%. An NPM1 mutation was noted in 31 patients (44%) who had improved OS (3‐year OS, 32% vs. 16%; p = .04). Allogeneic stem cell transplantation led to a trend toward improved OS in patients who had NPM1 wt AML (3‐year OS, 75% vs. 27%; p = .1) but not in those who had NPM1 mut AML. In the NPM1 mut / FLT3 ‐TKD wt cohort ( n = 126), intensive chemotherapy was received by 46 patients (37%), and lower intensity therapy was received by 80 patients (63%). Compared with the NPM1 mut / FLT3 ‐TKD mut cohort, no difference in OS was noted between patients who received intensive chemotherapy and those who received lower intensity therapy. Conclusions FLT3‐ TKD mut AML commonly harbors NPM1 co‐mutation, which has key prognostic implications. Lack of NPM1 co‐mutation portends a poor prognosis, and allogenic stem cell transplantation should be strongly considered for patients in first remission.
Year:
2025
PURPOSE The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy (IC)–ineligible AML: venetoclax (VEN) in combination with hypomethylating agent (HMA) therapy and azacitidine (AZA) plus ivosidenib (IVO) specifically for IDH1 -mutated AML. Although both regimens have improved AML outcomes, most patients will either not respond to frontline therapy or relapse, with dismal salvage outcomes. METHODS We herein report on 60 newly diagnosed IC-ineligible patients treated at our institution with triplet regimens for isocitrate dehydrogenase ( IDH )–mutant AML. Patients received either AZA + VEN + IVO on NCT03471260 ( IDH1 -mutated patients only) or oral decitabine + VEN + IVO/enasidenib on NCT04774393 (arms for IDH1- and IDH2 -mutant disease, respectively). RESULTS The triplet regimens were well tolerated with low early mortality (n = 1 [2%] in 60 days) and a similar safety profile to HMA + VEN and isocitrate dehydrogenase inhibitor doublet regimens. The composite complete remission rate (CRc) was 92% (55/60), with an overall response rate of 95% (57/60). With a median follow-up of 27.4 months, the median overall survival (OS) has not yet been reached. The 2-year OS was 69% with a 2-year cumulative incidence of relapse of 24%. Patients with treated-secondary AML (tsAML) experienced inferior outcomes with a CRc of 71% (12/17) and a 2-year OS of 34%; the 2-year OS was 84% in patients without tsAML. Nineteen patients (32%) transitioned to stem cell transplant, and 51% remain on study. CONCLUSION Given the excellent outcomes of IDH-triplet therapy for newly diagnosed, IC-ineligible IDH -mutant AML, further prospective studies comparing IDH-triplet versus IDH-doublet regimens are warranted.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Outcomes in patients with relapsed/refractory (RR) AML are poor. We sought to investigate if CPX‐531 in combination with venetoclax (CPX + VEN) was tolerable and effective in RR AML. This was a single institution phase 1b/2 trial of CPX + VEN. Patients aged ≥ 18 years with RR AML who were fit for intensive chemotherapy were eligible. Prior venetoclax exposure was allowed. The phase 1b portion followed a 3 + 3 design to identify the recommended phase 2 dose (RP2D) for the expansion cohort. At the starting dose level of −1, prolonged myelosuppression was observed, leading to dose level −2 (CPX‐351 dosed at daunorubicin 44 mg/m 2 on days 1,3, and 5 and venetoclax 300 mg days 2–8) being chosen as the RP2D. Thirty three patients with a median age of 58 years (range, 26–72) were treated. Patients were heavily pretreated, with 58% with prior venetoclax exposure, 44% in the second salvage or later, and 30% with prior stem cell transplant (SCT). Adverse cytogenetics were present in 51% of patients, with myelodysplasia‐related mutations in 64%, and TP53 mut in 21%. The overall response rate (ORR) was 46% (95% CI, 30–62), with a composite CR rate (CRc) of 39% (95% CI, 25–56). Patients in first salvage with wildtype TP53 had a CRc rate of 70% (95% CI, 40–89), with undetectable MRD in 71% (95% CI, 36–92) and a 2‐year OS of 49% (95% CI, 23–100). Eleven (73%) responding patients underwent SCT. The 30‐day mortality was 9%, with a 60‐day mortality of 21%. The most common adverse events were related to myelosuppression. CPX + VEN has activity in RR AML, particularly when used in first salvage and in patients who do not harbor TP53 mutations. ClinicalTrials.gov Identifier: NCT03629171
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Collaborators (19)
Samuel Urrutia
Assistant Professor of Medicine
Washington University in St. Louis
Gautam Borthakur
The University of Texas MD Anderson Cancer Center
Hussein A. Abbas
The University of Texas MD Anderson Cancer Center
Melissa Ooi
Assistant Professor of Medicine
National University of Singapore (NUS)
Jayastu Senapati
Assistant professor
The University of Texas MD Anderson Cancer Center
Alex Bataller Torralba
The University of Texas MD Anderson Cancer Center
Ghayas C. Issa
Assistant Professor
The University of Texas MD Anderson Cancer Center
Daria Babushok
University of Pennsylvania
Koichi Takahashi
The University of Texas MD Anderson Cancer Center
Koji Sasaki
Chair and Professor
The University of Texas MD Anderson Cancer Center
Patrick Reville
Assistant Professor
The University of Texas MD Anderson Cancer Center
Jennifer Croden
University of Alberta
Tapan M. Kadia
The University of Texas MD Anderson Cancer Center
Elias J. Jabbour
Professor
The University of Texas MD Anderson Cancer Center
Courtney D. DiNardo
University of Pennsylvania
Alessandra Ferrajoli
Docenti di ruolo di Ia fascia
The University of Texas MD Anderson Cancer Center
Musa Yilmaz
The University of Texas MD Anderson Cancer Center
Wei Wen Teo
Senior Research Fellow
Duke-NUS Medical School
Naval G. Daver
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.